Bristol-Myers Squibb Essays - Bristol-Myers Squibb, Clairol

Bristol-Myers Squibb Michael Zouroudis Cornerstone student in the College of Business Administration University of Central Florida October 15, 1999 Table of Contents Section Introduction/Executive Summary................................................................................................................3 Background..................................................................................................................................................4 Marketing Product/Service..................................................................................................................6 Place/Distribution..............................................................................................................7 Promotion/Advertising.......................................................................................................8 Management /Human Resources Training and Development................................................................................................9 Compensation and Rewards..............................................................................................9 Labor relations.................................................................................................................10 Finance Profitability and Cash Flow..............................................................................................10 Liquidity...........................................................................................................................12 Leverage/Capital Management........................................................................................13 Conclusion...................................................................................................................................13 References...................................................................................................................................14 Introduction and Executive Summary This document consists of an overall business review for the Pharmacuetical company Bristol-Myers Squibb. Although by no means a complete summary of their 1998 business dealings or stragety, it does give a nice overview of three of the most component and fundmentally sound aspects of any business, let alone a Fortune 500 business. This document starts by covering the Marketing aspect of Bristol-Myers Squibb. First covered is the most important structure of any company; its product. Inside is information on how they distribute their product, and where they distribute it to. Finally, we see how they promote their product, and which ways it is advertised. Management is the next topic of discussion. What style of management does Bristol-Myers Squibb conduct? The document talks about compensation given to their employees, and how the average employee is rewarded for acheving the unaverage level of excellence. Finally, the document focuses on Finance. It shows Bristol-Myers Squibb profits, it debts, how much money is invested in the company, and basically the direction that the Company is headed. Once again, this document is not nearly a complete breakdown of Bristol-Myers Squibb's 1998 business transactions. All this document is aiming for is to give an idea of the extreme complexity of the business world, understand(at least a little more) the strategy and competitiveness between companies, and maybe to enlighten a few on how much time and effort goes into such a giant of a company like this. Enjoy. History Bristol-Myers In 1887 William McLaren Bristol and John Ripley Myers decided to sink $5,000 into a failing drug manufacturing firm called the Clinton Pharmaceutical Company, located in Clinton, New York. The company was officially incorporated on December 13, 1887, with William Bristol as president and John Myers as vice president. In May 1898 came a new name: Bristol, Myers Company (a hyphen replaced the original comma after Myers's death in 1899 when the company became a corporation). The postwar depression prompted Bristol-Myers to jettison its ethical drug business and devote itself entirely to its specialties: its two big winners and a dozen or so assorted toiletries, antiseptics and cough syrups. Company headquarters was established in Manhattan, where it has remained ever since. And having shifted squarely into the consumer products arena, Bristol-Myers began advertising its products directly to the public. In 1924, gross profits topped $1 million for the first time in Bristol-Myers history. The company's products were on sale in 26 countries. At this point, the shares held by John Myers's heirs became available for sale, triggering a series of moves that turned Bristol-Myers into a publicly held company, listed on the New York Stock Exchange in 1929. In 1943, Bristol-Myers bought Cheplin Biological Labs, and quickly entered into the field of antibiotics. During the war, Bristol-Myers was a major distributor of penicillin and other types of antibiotics. By the end of the war, it was clear that penicillin and other antibiotics represented an immense opportunity for the company. Cheplin was renamed Bristol Laboratories, and Frederic N. Schwartz was put in charge of it. In 1957 Schwartz was appointed president and chief executive officer of Bristol-Myers when Henry Bristol chose to shed some of his former responsibilities and become chairman of the board. Reviewing the company's situation and prospects, Schwartz and then treasurer Gavin K. MacBain -- later Schwartz's successor as CEO -- decided that Bristol-Myers should embark on a program of acquiring well-managed smaller companies. The two executives' first major move in that direction was to acquire Clairol. Within a dozen or so years after Clairol joined the company, a number of other acquisitions followed, including those of Drackett, Mead Johnson, Zimmer and Westwood. In 1986 the company opened a state-of-the-art research complex in Wallingford, Connecticut, designed to house more than 800 scientists and support staff. In January 1994 Charles A. Heimbold, Jr., was elected chief executive officer. In 1995 Heimbold also became chairman. Squibb In 1856 Edward Robinson Squibb founded a pharmaceutical company in Brooklyn, New York, dedicated to the production of consistently pure medicines, like ether and chloroform. In 1905 the company was sold to Lowell M. Palmer

Could the self be an illusion

Could the self be an illusion The self, defined as an absolute, unchanging entity, which possesses unity, continuity and clear boundaries, may well be an illusion.Unity and continuity are easily disrupted in the normal course of life; they may be merely coincidental. Our supposedly unchanging selves do in fact alter according to their circumstances; the boundaries of the self change and a single self may even split to form multiple selves. By examining the self in terms of unity, continuity and boundaries, I will show how the possibilities for disruption of the self, as defined above, imply that it could be an illusion.Unity of a self implies that there is something that unites all my thoughts, feelings and experiences, i.e. that there is some sort of glue that makes them all true of me. The tendency is to call the glue the "self". Locke defined this as consciousness, that is, a person being "self to itself" by its consciousness of its present thoughts and actions .English: Neural Correlates Of ConsciousnessSo a single seat of consciousness may be termed a single self.This definition holds for my waking hours; however, there are obvious disruptions. What happens when I am anaesthetized, or fall into a deep sleep? I am not conscious of my present thoughts; I cannot even be said to have any "present thoughts". There are no experiences to be glued together, and there is no glue to bind them. Even when I dream, I may not be myself in my dream; I may, for example, be a butterfly . If the unified "I", as defined above, can somehow cease to exist for a time or be different things at different times, then unity, as defined by Locke, may be merely coincidental.The second question is that of continuity, that is, the sameness of the self over time.